安体优I抑制肿瘤淋巴管生成的实验研究

目的：观察安体优I对615小鼠HCa—F肝癌淋巴道转移的影响，探讨其作用机理。方法：生理盐水、干扰素和安体优1分别作用于动物模型，3周后检测转移淋巴结计数及转移率；免疫组化检测VEGF—C和Flt-4，5’-Nase—ALP双重组织化学法检测淋巴管微密度。结果：模型组、0l—IFN组和中药组转移淋巴结计数分别为5．88±2．30、4．13zl：1．64和3．50±1．91个；淋巴结转移率分别为78．6％、61．1％和57．4％；微淋巴管密度分别为25．25±4．59、22．384-4．41和21．75±4．71；VEGF—c的阳性率分别为87．5％、25．0％和25．0％，Fit-4阳性率分别为100．O％、37．5％和50．0％，中药组与模型组比较有显著性差异（P〈0．05）；结论：安体优I具有抑制615小鼠HCa—F肝癌淋巴道转移作用，其机制可能与下调淋巴管生成信号通路VEGF—c及其受体Fit-4的表达，抑制肿瘤淋巴管生成相关。

The experiment research of inhibitory effect of ATU - I on lymphangiogenesis of HCa - F liver cancer in 615 mice

Objective： To observe the inhibitory effect of ATU - I on lymphatic metastasis of HCa - F liver cancer in 615 mice. Methods： To treat the mice model with NS,α -IFN and ATU - I ,count the number of metastasized lymph node and rate of metastasis 3 weeks later; detect the expression of VEGF - C and Fh - 4 with immunohisto- chemical method; detect the micro - lymph duct density （MLD） with 5＇ - Nase - ALP double staining method. Re- suits ： In Model group, α - IFN group and ATU - I group, the number of metastasized lymph node were 5.88 ＋ 2.30, 4.13 ± 1.64 and 3.50 ± 1.91, the rates of metastasis of lymph node were 78.6% ,61.1% and 57.4% ;MLD were 25.25±4.59,22.38±4.41 and 21.75±4.71 ,the positive rates of VEGF - C were 87.5% ,25.0% and 25.0% ,the positive rates of Fit -4 were 100.0% ,37.5% and 50.0% ,comparing with Model group,there was a significance different in ATU - I group（P 〈0.05）. Conclusion： There is the effect of inhibition to the metastasis of lymphdute of HCa - F liver cancer in 615 mice treated with ATU - I,and the mechanism relates with down regulate of VEGF - C/ Flt- 4 and inhibition of lymphangiogenesis of liver cancer.